Phaseline

Companies › Formycon

Formycon: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FYB206
PD-1 inhibitor (anti-PD-1 antibody)
PDCD1Phase 1Melanoma, Stage II–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06551064FYB206Phase 1Melanoma, Stage IIOncologyDec 2025

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.